Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.55 |
| ▸ | NOS1 | P29475 | 1/20 | 0.55 |
| ▸ | NOS2 | P35228 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 6/20 | 0.41 |
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | CTSK | P43235 | 8/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237559 | 1.00 | NOS3 (0.55) | NOS3NOS1NOS2PPARAPPARG | |
| SCHEMBL29690693 | 0.90 | NOS3 (0.48) | NOS3NOS1NOS2PPARAPPARG | |
| SCHEMBL5966544 | 0.87 | REN (0.49) | NOS3NOS1NOS2PPARAPPARG | |
| SCHEMBL7369111 | 0.86 | NOS3 (0.52) | NOS3NOS1NOS2PPARAPPARG | |
| SCHEMBL11024821 | 0.84 | NOS3 (0.42) | NOS3NOS1NOS2PPARAPPARG | |
| SCHEMBL8376056 | 0.81 | NOS3 (0.46) | NOS3NOS1NOS2CTSK | |
| SCHEMBL6957795 | 0.80 | CTSK (0.44) | PPARAPPARGCTSKCTSSALDH1A1 | |
| SCHEMBL5966560 | 0.80 | REN (0.47) | CTSKCTSS | |
| SCHEMBL30619504 | 0.79 | CTSL (0.44) | NOS3NOS1NOS2CTSKCTSS | |
| SCHEMBL5966478 | 0.79 | CTSS (0.51) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104356196-A | Oligopeptide based reductive sensitive lipid derivative and application of derivative in drug delivery | UNIV CHINA PHARMA | 2015-02-18 | — | — | CN | disclosed |
| US-20060128613-A1 | Melanocortin receptor ligands | THE PROCTER & GAMBLE COMPANY | 2006-06-15 | — | — | US | disclosed |
| EP-1409540-A2 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2002026774-A2 | MELANOCORTIN RECEPTOR LIGANDS | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128613-A1 | Melanocortin receptor ligands | MC3R, MC4R, MC1R | NOS3 2858/4885NOS1 4628/4885NOS2 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.